In areas of relatively low and unstable malaria transmission, the rate is accelerated by lack of immunity which may otherwise
serve to remove drug resistant parasites or gametocytes with resulting reduction in transmission (Peel et al., 1993; Lensen et. al., 1998; Hogh et. al.,
1998; McKenzie & Bossert, 1998). Patients resident in these areas are symptomatic and seek treatment, bringing infections under selective drug pressure, while multiple infections are rare resulting in limited opportunity for loss of resistance through recombination breakdown due to outbreeding (Watkins & Msobo, 1993; Hill
et. al., 1995; Hastings, 1997). Outbreeding slows the spread of resistance (Dye et. al., 1997). Mature gametocytes of P. falciparum are insensitive to many schizontocidal
drugs, including chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) (Smalley and Sinden, 1997; Sinden 1983) with resultant survival of mature gametocytes of drug-sensitive parasites until the end of their
natural life span (14 - 28 days) despite treatment. Further decline in antimalarial drug efficacy results in a rise in the proportion of resistant infections, increased gametocyte carriage and greater
transmission of resistant strains of P. falciparum
with accelerated decline in drug sensitivity. On the other hand effective drugs with rapid action on asexual stages of the parasites limit gametocytogenisis (Price et. al.,
1996). Chloroquine induces increased gametocytemia in chloroquine resistant lines (Handunnetti et. al., 1996; Roberts et. al.,
1996) while SP induces increased gametocytemia in both SP-sensitive and SP resistant-lines (Hogh et al., 1995; Puta & Manyando, 1997; Hogh et.al. 1998; Govere et. al., 1999).
Gametocytemia can be reduced by early treatment with an effective drug or by use of gametocytocidal agents (Sinden et. al.,
1996). The artemisinin derivatives dramatically reduce gametocyte carriage through their rapid effect on asexual parasites (Price et. al.,
1996, 1997). Furthermore artemisinin derivatives in combination with other antimalarial drugs delay drug resistance (White 1998), ensure high malaria cure rates (White et al.,
1999) and reduce gametocyte carriage (Price et. al., 1997, 1999) during the treatment of malaria.
In the proposed study, gametocytes will be harvested from patients recruited for the multi-centre in vivo
malaria monotherapy resistance studies and subsequent study of the in vivo effectiveness of Artesunate plus SP combination for the treatment of uncomplicated falciparum malaria in southern Africa. OBJECTIVES To determine the association between the type of antimalarial drug administered and the level of P.
falciparum gametocytemia prevalence and density (at all study sites). To determine infectivity of gametocytes persisting in the host following administration of an effective
schizontocidal (in Mpumalanga).
References
|